Speakers

​CV of Symposium Speakers and Publication list

​CV of Symposium Speakers

Alberto Bedogni. University of Padova, Italy

Dr. Alberto Bedogni is Director of the Regional Center for Prevention, Diagnosis and Treatment of Medication and Radiation-related Bone Diseases of the Head and Neck since 2014. He is Assistant professor of Maxillofacial Surgery at the Department of Neurosciences-DNS, University of Padua, and Consultant at the Unit of Maxillofacial Surgery, Hospital Trust of Padua. His basic and clinical research focuses upon osteonecrosis of the jaws, bio-molecular markers in head & neck cancer, peripheral nerve regeneration, regenerative medicine and development of CAD-CAM customized titanium prototypes for jawbone reconstruction.  He is coordinator of the Expert Panel Committee of the Italian Societies of Maxillofacial Surgery (SICMF) and Oral Medicine and Pathology (SIPMO) and is co-author of the Italian Recommendations for the prevention, diagnosis and treatment of MRONJ published in 2013. He also actively contributed to the preparation of the guidelines on prevention of bisphosphonate-related ONJ in the cancer population, on behalf of the Italian Ministry of Health (2014). He has been coordinator of a research team who published several clinical papers in the last 10 years on the prevention, treatment and pathogenesis of BRONJ and few of the very initial reports on bevacizumab and sunitinib-related ONJ. He contributed to develop an international network of clinical research centres and promoted several multicentre studies on MRONJ.

Stefano Fedele. Eastman Dental Hospital, London, England

Dr Stefano Fedele is Head of Department of Clinical Research at University College London, Eastman Dental Institute and Senior Clinical Lecturer in Oral Medicine. His research activities focus upon clinical and translational research in Oral Medicine with a special interest in MRONJ. Through international collaboration he set up a network of centres collecting clinical data and DNA of a large cohort of MRONJ patients and drug-exposed controls to inform clinical and pharmacogenetic (genetic predisposition) studies. He has led a team of international investigators to publish a number of research papers on the non-exposed variant of MORNJ.  the inaccuracy of MRONJ definition and classification, and the need for CT scan for accurate staging of MRONJ. He has also reported on the time to onset of MRONJ and the management of patients at risk of MRONJ. Twenty-eight sites from seven countries have contributed to his Genome Wide Association study (GWAs), which over the last 7 years has collected DNA from ~1,000 MRONJ patients and drug-exposed controls, and is currently in the replication phase with final results expected in late 2017.

Roman Guggenberger. University of Zurich, Schwitzerland

Dr. Roman Guggenberger was born in Innsbruck, Austria where he studied medicine at the Medical University. After training and obtaining full license as a general practicioner in Austria, he moved to Zürich, Switzerland and finished his training in general radiology at the Department of Diagnostic and Interventional Radiology. He was fellow at the radiology department of the Orthopedic University Hospital in Zürich and subspecialized in musculoskeletal radiology and also performed a fellowship in pediatric neuroradiology at the Children`s Hospital in Zürich. He has obtained the Swiss diploma of diagnostic neuroradiology and became associate professor in 2016. Dr. Guggenberger is now a senior staff member and head of the musculoskeletal radiology imaging and research group at the Department of Diagnostic and Interventional Radiology in Zürich. He has spent most of this research career in evaluation and optimization of different imaging techniques for diseases of the musculoskeletal system. A strong focus of his work is on cone-beam CT in its various forms and peripheral nerve imaging. He has also published several works on bisphosphonate-induced osteonecrosis of the jaw and its detectability in different imaging techniques.

Ourania Nicolatou-Galitis. University of Athens, Greece

Ourania Nicolatou-Galitis, DDS, MSc, DrDEnt, Ourania Nicolatou-Galitis, www.nicolatou-galitis.com,  www.dentaloncology.gr, www.dentaloncology.eu. Oral Medicine, Oral Oncologist, Professor of the National and Kapodistrian University of Athens, Dental Oncology Unit, Dental School, dent.uoa.gr. Dr Ourania Nicolatou-Galitis graduated from the Dental School of the National and Kapodistrian University of Athens. She obtained her Master's Degree and Certificate in Oral Pathology from Temple University, Philadelphia, USA.

Current positions

  • Professor and Head, Clinic of Hospital Dentistry, 2010-present
  • Responsible of the Graduate Program in Hospital Dentistry, 2010-present
  • Founding member and President of the Hellenic Society of Oral Oncology,   oraloncology.gr, 2005-present
  • Founding member and member of the Board of the Hellenic Society of Head and Neck Cancer, headneckcancer.gr, 2016-present
  • Past President of the International Society of Oral Oncology-ISOO, 2017-2019
  • MASCC Strategic Planning Committee, mascc.org, 2017-2020
  • Chair of the Bone Study Group, mascc.org, 2015-2020

Osteonecrosis of the jaw in medication is currently the main clinical and research focus of Dr Ourania Nicolatou-Galitis. She serves as a referral center for many Cancer Centers of Greece. She is the principal investigator for the AMGEN Registry Study for osteonecrosis in the Athens Dental School Center.

Sven Otto. Ludwig-Maximilians-University of Munich, Germany

PD Dr. med. Dr. med. dent. Sven Otto has dealt intensively with clinical presentation, pathogenesis, prevention and treatment of medication-related osteonecrosis of the jaw. He has developed a pathogenesis theory putting infection and infection associated ph changes in the centre of the focus and collected cell cultural and clinical evidence for this hypothesis. He has also contributed to the clinical implementation of fluorescence-guided surgery for the treatment of MRONJ. Together with the AO research institute in Davos a minipig large animal model for MRONJ was established which could contribute to the further understanding of MRONJ. Together with Springer publishing he has edited the textbook "Medication-related osteonecrosis of the jaw: Bisphosphonates, Denosumab and New Agents".

  • 1997-2006 Dental and medical studies at the university of Leipzig (Germany)
  • 2006-2012: Specialty training for Oral and Maxillofacial Surgery, LMU München
  • seit 05/2012: Board examination for Oral and Maxillofacial Surgery, LMU of Munich
  • 2013: Habilitation dealing with „Bisphosphonate-related osteonecrosis of the jaw"
  • since 2013 Senior Consultant of the department of Oral and Maxillofacial Surgery of Ludwig-Maximilians-University of Munich (Head: Professor Dr. Dr. Michael Ehrenfeld)
  • 2014 Editor: Medication-Related Osteonecrosis of the Jaw: Bisphosphonates, Denosumab and New Agents" (published by Springer)
  • 2015 Scientific Award of the German Association of Oral and Maxillofacial Surgery: „From cell culture over the large animal towards optimization of the prophylaxis and treatment of medication-related osteonecrosis of the jaw"

Thomas Kofod. Rigshospitalet, Copenhagen University Hospital, Denmark

Dr Thomas Kofod is Head of Department of Oral and Maxillofacial Surgery at Rigshospitalet (Copenhagen University Hospital). His clinical and research activities focus upon corrective and reconstructive craniofacial and maxillofacial surgery including computer assisted surgery.  In BRONJ especially computer assisted resection and reconstruction has been the focus of interest. In close collaboration with Morten Schiødt he parts the Copenhagen research team on BRONJ.

Morten Schiodt. Rigshospitalet, Copenhagen University Hospital, Denmark

Morten Schiodt is Senior Consultant, DDS, Dr. odont. Specialist Degree in Oral & Maxillofacial Surgery, Copenhagen (Rigshospitalet), Denmark, in 1979. Doctoral thesis on Oral Manifestations of Lupus Erythematosis in 1984. Teaching and organized symposia in 25 countries. Research on Sjogren's Syndrome, HIV/AIDS, and on Osteonecrosis of the jaws from antiresorptive treatment.

Chairman of the Department of Oral & Maxillofacial Surgery, Cph. Univ. Hospital 2001-2011. President of the Danish Association Oral & Maxillofacial Surgery for 6 years (1984-86 and 89-91), President of the Danish Society of Oral & Maxillofacial Surgery for 6 years (1996-2002), Assoc. Prof. University of California, San Francisco, USA, 1986-1989. Scientific reviewer 13 international Journals. Director of SICCA-Denmark founded in 2003,  part of NIH-funded multicenter project leading to new classification of Sjogren's Syndrome. NIH funding 12.5 mill $. Author or co-author of 186 publications.

Present positions

  • Senior Maxillofacial Consultant at Department of Oral & Maxillofacial Surgery, Copenhagen University Hospital (Rigshospitalet) , Denmark
  • 2003 – now: Director of SICCA Denmark. Part of multinational Sjogren project.
  • 2010 - now: Director of Osteonecrosis Research at Copenhagen University Hospital, Denmark.
  • 2010 - now: Director of Copenhagen ONJ Cohort (288 patients)
  • 2011 – now: Scandinavian Coordinator for Scandinavian ONJ Database (Amgen XGEVA-363-study). 1000 patients enrolled.
  • 2014 – now: European Lead Investigator for a Global Multicenter Case registry ONJ study (Amgen 2010-1102 study), 64 sites, 275 patients enrolled.

 

Download publication list


Responsible editor